Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | BAZ1A | Q9NRL2 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660021 | 0.83 | THRB (0.46) | SMN1; SMN2PTPN11MAPTNPC1RAB9A | |
| SCHEMBL10630197 | 0.74 | BAZ1A (0.47) | SMN1; SMN2MAPTNPC1RAB9AKDM4E | |
| SCHEMBL2211494 | 0.74 | ALDH1A1 (0.46) | MAPTNPC1RAB9AKDM4EGAA | |
| SCHEMBL1291431 | 0.74 | NPC1 (0.42) | MAPTNPC1RAB9AALDH1A1POLB | |
| SCHEMBL14582771 | 0.73 | THRB (0.42) | SMN1; SMN2MAPTNPC1RAB9AKDM4E | |
| SCHEMBL1291502 | 0.71 | NSD2 (0.59) | SMN1; SMN2NPC1RAB9AALDH1A1BAZ1A | |
| Benzene SCHEMBL28730813 | 0.70 | MAPT (0.39) | SMN1; SMN2MAPTNPC1RAB9AKDM4E | |
| SCHEMBL10634714 | 0.69 | PRMT3 (0.51) | MAPTNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL507524 | 0.69 | PRMT3 (0.45) | MAPTNPC1RAB9AALDH1A1POLB | |
| SCHEMBL29567889 | 0.69 | PRMT3 (0.45) | MAPTNPC1RAB9AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865912-B | AQP9 inhibitor and preparation method and application thereof | 康替生物科技(杭州)有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-117865912-A | AQP9 inhibitor and preparation method and application thereof | 康替生物科技(杭州)有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117865912-B | AQP9 inhibitor and preparation method and application thereof | 康替生物科技(杭州)有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-117865912-A | AQP9 inhibitor and preparation method and application thereof | 康替生物科技(杭州)有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20200079786-A1 | ANALOGS OF ADAMANTYLUREAS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIVERSITAT DE BARCELONA (ES) | 2020-03-12 | — | — | US | disclosed |
| US-20190322632-A1 | HRI ACTIVATORS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | UNIVERSITAT DE BARCELONA (ES) | 2019-10-24 | — | — | US | disclosed |
| US-20190322632-A1 | HRI ACTIVATORS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | UNIVERSITAT DE BARCELONA (ES) | 2019-10-24 | — | — | US | disclosed |
| EP-3328854-A1 | ANALOGS OF ADAMANTYLUREAS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Universitat de Barcelona (ES) | 2018-06-06 | — | — | EP | disclosed |
| US-9920044-B2 | Selective androgen receptor modulators | RADIUS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920044-B2 | Selective androgen receptor modulators | RADIUS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920044-B2 | Selective androgen receptor modulators | RADIUS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20030095914-A1 | In the absence of an externally applied electric current sufficient to reduce the diazonium salt and attach an organic group; improved abrasion resistance. | BELMONT JAMES A (US) | 2003-05-22 | — | — | US | disclosed |
| US-6494946-B1 | PROCESSES FOR PREPARING A CARBON BLACK PRODUCT HAVING AN ORGANIC GROUP ATTACHED TO THE CARBON BLACK. IN ONE PROCESS AT LEAST ONE DIAZONIUM SALT REACTS WITH A CARBON BLACK IN THE ABSENCE OF AN EXTERNALLY APPLIED ELECTRIC CURRENT SUFFICIENT | CABOT CORPORATION | 2002-12-17 | — | — | US | disclosed |
| EP-0799281-B1 | CARBON BLACK REACTED WITH DIAZONIUM SALTS AND PRODUCTS | CABOT CORP (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1225205-A2 | Carbon black reacted with diazonium salts and products | CABOT CORPORATION (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6042643-A | AS PIGMENT TO COLOR PLASTICS, PAPER, TEXTILE, RUBBER, AQUEOUS INKS | CABOT CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| US-5900029-A | COLORING FIBER OR TEXTILE | CABOT CORPORATION (US) | 1999-05-04 | — | — | US | disclosed |
| US-5851280-A | Reaction of carbon black with diazonium salts, resultant carbon black products and their uses | CABOT CORPORATION (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0799281-A1 | CARBON BLACK REACTED WITH DIAZONIUM SALTS AND PRODUCTS | CABOT CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996018688-A1 | CARBON BLACK REACTED WITH DIAZONIUM SALTS AND PRODUCTS | CABOT CORPORATION (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079786-A1 | ANALOGS OF ADAMANTYLUREAS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | SMN1; SMN2 3579/4885PTPN11 3218/4885MAPT 4551/4885 |
| US-20190322632-A1 | HRI ACTIVATORS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | NR1I2, HMOX1, HMOX2 | SMN1; SMN2 3966/4885PTPN11 3210/4885MAPT 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.